Reaching Deep Remissions with a New Therapy for Multiple Myeloma Patients

 Roswell Park is spearheading efforts to study innovative CAR T-cell therapies in addition to offering traditional treatment approaches.  Investigations to improve therapy outcomes for multiple myeloma are being led by experts such as Jens Hillengass, MD, PhD, Chief of Myeloma at Roswell Park Comprehensive Cancer Center; featured in our informational video. In addition, research at Roswell Park Comprehensive Cancer Center focuses on strategies to reverse immune dysfunction to prevent infections and control the endogenous immune response to multiple myeloma. Abecma, a new cellular therapy approach, is disrupting traditional approaches by offering patients who have no other treatment options left an opportunity for remission.

Related Presenters

Jens Hillengass, MD, PhD.

Jens Hillengass, MD, PhD

Chief of Myeloma, Professor of Oncology

While in Medical School I focused my research on the investigation of morphological and functional imaging of hematological diseases, especially monoclonal plasma cell disorders. Our group has established magnetic resonance imaging (MRI) ...

View full profile


Related Videos